Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | HAT1 | O14929 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GLI1 | P08151 | 1/20 | 0.35 |
| ▸ | GLI2 | P10070 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646538 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3642249 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL27791247 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3646542 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3642250 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3642251 | 0.92 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3643441 | 0.90 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3643444 | 0.90 | TP53 (0.42) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3650154 | 0.90 | TP53 (0.45) | TP53POLBKMT2AMEN1CTSB | |
| SCHEMBL3650150 | 0.90 | TP53 (0.45) | TP53POLBKMT2AMEN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | TP53 4876/4885POLB 3444/4885KMT2A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.